Thiazolidinediones: do harms outweigh benefits?
Lipscombe
Lorraine L
LL
Institute for Clinical Evaluative Sciences, Department of Medicine, University of Toronto, and Women's College Hospital, Toronto, Ont. Lorraine.Lipscombe@ices.on.ca
D015519:Bone Density / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000453:epidemiology; D005260:Female; D050723:Fractures, Bone / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D000077205:Pioglitazone; D018570:Risk Assessment; D012307:Risk Factors; D000077154:Rosiglitazone; D012737:Sex Factors; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077205:Pioglitazone